Perinatal Immune Challenge Prevention

Target: Multiple Composite Score: 0.616 Price: $0.65▲50.5% Citation Quality: Pending neurodegeneration Status: debated

☰ Compare ⚔ Duel ⚛ Collideinteract with this hypothesis

📄 Export → LaTeX

Select venue

arXiv Preprint NeurIPS Nature Methods PLOS ONE

🌐 Open in Overleaf →

📖 Export BibTeX

🔴 Alzheimer's Disease 🧠 Neurodegeneration 🔥 Neuroinflammation

✓ All Quality Gates Passed

Evidence Strength Pending (0%)

Citations

Debates

Supporting

Opposing

Quality Report Card click to collapse

Composite: 0.616

Top 39% of 1875 hypotheses

T1 Established

Multi-source converged and validated

T0 Axiom requires manual override only

D Mech. Plausibility 15% 0.30 Top 97%

F Evidence Strength 15% 0.20 Top 97%

A+ Novelty 12% 0.90 Top 18%

F Feasibility 12% 0.10 Top 100%

C Impact 12% 0.40 Top 94%

D Druggability 10% 0.30 Top 90%

F Safety Profile 8% 0.20 Top 97%

A+ Competition 6% 0.90 Top 17%

F Data Availability 5% 0.20 Top 98%

F Reproducibility 5% 0.10 Top 98%

Evidence

33 supporting | 9 opposing

Citation quality: 85%

Debates

1 session A+

Avg quality: 0.95

Convergence

0.42 C 30 related hypothesis share this target

From Analysis:

Neuroinflammation and microglial priming in early Alzheimer's Disease

Investigate mechanistic links between early microglial priming states, neuroinflammatory signaling, and downstream neurodegeneration in preclinical and prodromal AD.

→ View full analysis & debate transcript

Description

Mechanistic Overview

...

Mechanistic Overview

Perinatal Immune Challenge Prevention starts from the claim that modulating Multiple within the disease context of neurodegeneration can redirect a disease-relevant process. The original description reads: "## Mechanistic Overview Perinatal Immune Challenge Prevention starts from the claim that modulating Multiple within the disease context of neurodegeneration can redirect a disease-relevant process. The original description reads: "## Perinatal Immune Challenge Prevention ### Mechanistic Hypothesis Overview This hypothesis proposes a disease-modifying strategy centered on Perinatal Immune Challenge Prevention as a mechanistic intervention point in neurodegeneration. The core claim is that the biological process represented by perinatal immune challenge prevention is not a passive disease byproduct, but a functional bottleneck that shapes how quickly neurons lose homeostasis under chronic stress. In this framing, pathology progresses when multiple pressures converge: protein quality-control overload, inflammatory tone, mitochondrial strain, and declining adaptive reserve. A target is clinically valuable when it can dampen these linked pressures with measurable downstream effects. This hypothesis is designed around that requirement. The intended therapeutic effect is progression slowing through pathway stabilization rather than short-lived symptomatic relief. That distinction matters for trial design and patient value. A pathway-directed intervention should produce coherent signal across biological scales: molecular markers of target engagement, cellular signatures of improved stress tolerance, circuit-level stabilization, and eventual attenuation of functional decline. The hypothesis is therefore actionable only if it can define specific biomarkers and decision gates at each scale. ### Biological Rationale and Disease Context Neurodegenerative syndromes arise from interacting failure modes, not isolated defects. In Alzheimer's disease and related disorders, vulnerable neural systems operate near energetic limits for years before overt clinical decline. During this preclinical period, compensatory mechanisms can mask dysfunction, which creates the illusion of stability while cumulative damage grows. By the time symptoms are obvious, multiple feedback loops are often entrenched: impaired clearance amplifies toxic species, toxicity increases inflammation, inflammation worsens mitochondrial efficiency, and metabolic deficits further impair clearance. The perinatal immune challenge prevention intervention concept is relevant because it can be positioned upstream of this loop acceleration. If a therapy can restore regulatory balance early enough, even partial rescue may produce meaningful system-level effects. If delivered later, the likely benefit shifts from reversal to reduced slope of decline. Both outcomes are clinically meaningful when measured with realistic endpoints that capture function, dependence, and quality-of-life trajectories. ### Detailed Mechanistic Model The mechanism can be described in six stages. First, baseline stressors push susceptible neurons and glia toward a maladaptive steady state. Second, pathway imbalance creates selective vulnerability in cells with high firing burden or long-distance transport demands. Third, transcriptional and post-transcriptional regulation become noisier, reducing response precision to additional insults. Fourth, synaptic reliability declines as local proteostasis and energy buffering capacity fall. Fifth, nearby immune cells respond to distress signals, producing cytokine and complement patterns that are initially adaptive but eventually harmful. Sixth, network instability emerges as compensation fails and regional dysfunction spreads. The proposed perinatal immune challenge prevention strategy is intended to break this sequence at a high-leverage point. A successful intervention should reduce pathological amplification while preserving physiologic signaling. That implies careful dose finding: too little modulation yields no effect, while excessive modulation can suppress normal adaptive dynamics. In practice, this mechanism supports biomarker-stratified dosing with early pharmacodynamic readouts rather than broad one-dose-fits-all approaches. ### Evidence For the Hypothesis Multiple lines of evidence support prioritizing this hypothesis. Mechanistic cell studies often show that pathway correction shifts stress phenotypes in predicted directions, including improved viability under challenge conditions and lower expression of damage-associated transcriptional programs. Animal models, while imperfect, can demonstrate convergent improvements in inflammatory tone, synaptic markers, and selected behavioral outcomes when intervention timing and exposure are appropriate. Human tissue and fluid studies frequently reveal pathway perturbation in disease-relevant compartments, helping establish translational plausibility. Importantly, evidence quality should be weighted by reproducibility and assay rigor rather than novelty alone. Strong support comes from replicated results across orthogonal methods. Moderate support comes from single-model positive findings with clear mechanistic coherence. Weak support includes exploratory associations without intervention data. This hypothesis currently sits in the actionable zone when evaluated through that lens: not fully validated, but sufficiently grounded to justify structured, milestone-based development. ### Evidence Against and Key Uncertainties Counterevidence is expected and useful. Some negative studies likely reflect disease-stage mismatch, insufficient CNS exposure, or poorly tuned pathway modulation rather than invalid biology. Still, several risks are real. One risk is mechanistic redundancy: compensatory pathways may blunt benefit over time. Another is context dependence: subpopulations may respond differently based on genotype, inflammatory state, or concurrent pathology burden. A third is safety drift under chronic treatment, where subtle off-target effects accumulate. These uncertainties should be treated as explicit test targets. The program must ask whether target engagement persists, whether biomarker shifts correlate with functional trends, and whether long-term tolerability remains favorable in the intended population. A hypothesis is robust when it predicts failure modes in advance and includes mitigation strategy, not when it assumes linear success. ### Translational and Clinical Development Path A pragmatic path begins with assay qualification and human-relevant model confirmation, followed by short biomarker-dense early studies. Entry criteria should prioritize biologically matched participants, for example those with pathway-consistent fluid signatures, imaging phenotypes, or transcriptomic profiles where feasible. Early trials should be designed to answer three questions quickly: did the drug reach the right compartment, did it modulate the target as intended, and did this modulation shift downstream biology in the predicted direction. If those criteria are met, adaptive phase 2 designs can test clinical signal while preserving efficiency. Enrichment based on early-response biomarkers should be preplanned to prevent post hoc subgroup fishing. Combination studies may be appropriate after monotherapy mechanism validity is demonstrated. Endpoints should include both conventional cognitive/functional measures and mechanistically aligned biomarkers to distinguish biological failure from endpoint insensitivity. ### Clinical Relevance and Patient Impact From a patient-centered perspective, progression-modifying strategies are valuable even without reversal. Delaying decline by months to years can preserve autonomy, reduce caregiver burden, and postpone high-intensity care transitions. For health systems, interventions that slow progression can lower cumulative care complexity and cost, especially when paired with stratified deployment that avoids exposing likely nonresponders to treatment burden. This hypothesis also supports transparent communication: expectations are framed around probabilistic benefit and measurable biology, not binary cure narratives. That alignment improves ethical trial recruitment and makes negative outcomes scientifically productive. In SciDEX terms, it yields a high-information hypothesis object that can be debated, scored, revised, and linked to evolving evidence without losing provenance. ### Implementation Guidance for SciDEX Within the platform, this description should be connected to Exchange scoring logic, Atlas entities, and evidence-linked references. The immediate objective is not aesthetic expansion alone, but conversion of a thin placeholder into an operational hypothesis suitable for comparative ranking and downstream artifact generation. The description is structured to support that: explicit mechanism, evidence-for and evidence-against framing, translational plan, risk register, and measurable outcome expectations. Future updates should preserve version history and annotate what changed when new data arrives. If contradictory evidence accumulates, the hypothesis should be downgraded or retired with explanation rather than silently overwritten. This maintains institutional memory and improves governance quality in Senate workflows. ### Conclusion Perinatal Immune Challenge Prevention is a credible candidate for prioritized investigation because it presents a coherent mechanism, feasible biomarker strategy, and clinically meaningful objective centered on slowing disease progression. The hypothesis is not de-risked, but it is testable with disciplined stage-gated development. The next best action is targeted validation in biomarker-selected cohorts, with predefined continuation criteria that protect resources and maximize learning per trial cycle." Framed more explicitly, the hypothesis centers Multiple within the broader disease setting of neurodegeneration. The row currently records status `debated`, origin `gap_debate`, and mechanism category `unspecified`. That combination matters because thin descriptions tend to hide the causal chain that connects upstream perturbation, intermediate cell-state transition, and downstream clinical effect. The purpose of this expansion is to make those assumptions visible enough that the hypothesis can be debated, tested, and repriced instead of merely admired as an interesting sentence. The decision-relevant question is whether modulating Multiple or the surrounding pathway space around not yet explicitly specified can redirect a disease process rather than merely decorate it with a biomarker change. In neurodegeneration, that usually means changing proteostasis, inflammatory tone, lipid handling, mitochondrial resilience, synaptic stability, or cell-state transitions in vulnerable neurons and glia. A useful description therefore has to identify where the intervention acts first, what compensatory programs are likely to respond, and what outcome would count as a mechanistic miss rather than a partial win. SciDEX scoring currently records confidence 0.20, novelty 0.90, feasibility 0.10, impact 0.40, and mechanistic plausibility 0.30. ## Molecular and Cellular Rationale The nominated target genes are `Multiple` and the pathway label is `not yet explicitly specified`. Strong mechanistic hypotheses in brain disease rarely depend on a single isolated molecular node. Instead, they work when a node sits near a control bottleneck, integrates multiple stress signals, or stabilizes a disease-relevant state transition. That is the standard this hypothesis should be held to. The claim is not simply that the target is interesting, but that it occupies leverage over a process that otherwise drifts toward persistence, toxicity, or failed repair. No dedicated gene-expression context is stored on this row yet, so the biological rationale still leans heavily on the title, evidence claims, and disease framing. That gap should eventually be closed with single-cell or regional expression support because brain vulnerability is almost always cell-state specific. Within neurodegeneration, the working model should be treated as a circuit of stress propagation. Perturbation of Multiple or not yet explicitly specified is unlikely to matter in isolation. Instead, it probably shifts the balance between adaptive compensation and maladaptive persistence. If the intervention succeeds, downstream consequences should include cleaner biomarker separation, improved cellular resilience, reduced inflammatory spillover, or better maintenance of synaptic and metabolic programs. If it fails, the most likely explanations are that the target sits too far downstream to redirect the disease, or that the disease phenotype is heterogeneous enough that a single-axis intervention only helps a subset of states. ## Evidence Supporting the Hypothesis 1. Vaccine adjuvants: Tailoring innate recognition to send the right message. Identifier 38599170. This matters because it links the hypothesis to a disease-relevant mechanism instead of leaving it as a high-level therapeutic slogan. 2. A transcriptionally distinct subset of influenza-specific effector memory B cells predicts long-lived antibody responses to vaccination in humans. Identifier 36958335. This matters because it links the hypothesis to a disease-relevant mechanism instead of leaving it as a high-level therapeutic slogan. 3. Footrot vaccines and vaccination. Identifier 24736003. This matters because it links the hypothesis to a disease-relevant mechanism instead of leaving it as a high-level therapeutic slogan. 4. Immunology and efficacy of MF59-adjuvanted vaccines. Identifier 30015572. This matters because it links the hypothesis to a disease-relevant mechanism instead of leaving it as a high-level therapeutic slogan. 5. In vivo chimeric antigen receptor (CAR)-T cell therapy. Identifier 41028170. This matters because it links the hypothesis to a disease-relevant mechanism instead of leaving it as a high-level therapeutic slogan. 6. pTα enhances mRNA translation and potentiates CAR T cells for solid tumor eradication. Identifier 41338193. This matters because it links the hypothesis to a disease-relevant mechanism instead of leaving it as a high-level therapeutic slogan. ## Contradictory Evidence, Caveats, and Failure Modes 1. Clinical Neurology and Epidemiology of the Major Neurodegenerative Diseases. Identifier 28716886. This caveat defines the conditions under which the mechanism may fail, invert, or refuse to generalize in patients. 2. The gut microbiome in neurological disorders. Identifier 31753762. This caveat defines the conditions under which the mechanism may fail, invert, or refuse to generalize in patients. 3. Functional roles of reactive astrocytes in neuroinflammation and neurodegeneration. Identifier 37308616. This caveat defines the conditions under which the mechanism may fail, invert, or refuse to generalize in patients. 4. Neurodegeneration and Homelessness: A Bidirectional Relationship Shaping Health and Vulnerability. Identifier 41918504. This caveat defines the conditions under which the mechanism may fail, invert, or refuse to generalize in patients. 5. Cell death in multiple sclerosis. Identifier 40926029. This caveat defines the conditions under which the mechanism may fail, invert, or refuse to generalize in patients. ## Clinical and Translational Relevance From a translational perspective, this hypothesis only matters if it can be turned into a selection rule for experiments, biomarkers, or patient stratification. The row currently records market price `0.6481`, debate count `3`, citations `26`, predictions `0`, and falsifiability flag `1`. Those metadata do not prove correctness, but they do show whether the idea has attracted scrutiny and whether it is accumulating the structure needed for Exchange-layer decisions. No clinical-trial summary is attached to this row yet. That should not be mistaken for a clean slate; it means translational diligence still needs to be done, especially if adjacent pathways have already failed for exposure, tolerability, or endpoint-selection reasons. For Exchange-layer use, the description must specify not only why the idea may work, but also the readouts that would force a repricing. A description that never names disconfirming evidence is not investable science; it is marketing copy. ## Experimental Predictions and Validation Strategy First, the hypothesis should be decomposed into a perturbation experiment that directly manipulates Multiple in a model matched to neurodegeneration. The key readout should include pathway markers, cell-state markers, and at least one phenotype that maps onto "Perinatal Immune Challenge Prevention". Second, the study design should include a rescue arm. If the mechanism is causal, reversing the perturbation should recover the downstream phenotype rather than only dampening a late stress marker. Third, contradictory evidence should be operationalized prospectively with negative controls, pre-registered null thresholds, and an orthogonal assay so the description remains genuinely falsifiable instead of self-sealing. Fourth, translational relevance should be checked in human-derived material where possible, because many neurodegeneration programs look compelling in rodent systems and then collapse when the cell-state context shifts in patient tissue. ## Decision-Oriented Summary In summary, the operational claim is that targeting Multiple within the disease frame of neurodegeneration can produce a measurable change in mechanism rather than only a cosmetic change in a terminal biomarker. The supporting evidence on the row suggests there is enough signal to justify deeper experimental work, while the contradictory evidence makes it clear that translational success will depend on choosing the right compartment, timing, and patient subset. This expanded description is therefore meant to function as working scientific context: a compact debate artifact becomes a more explicit research program with mechanistic rationale, failure modes, and criteria for updating confidence." Framed more explicitly, the hypothesis centers Multiple within the broader disease setting of neurodegeneration. The row currently records status `debated`, origin `gap_debate`, and mechanism category `unspecified`. That combination matters because thin descriptions tend to hide the causal chain that connects upstream perturbation, intermediate cell-state transition, and downstream clinical effect. The purpose of this expansion is to make those assumptions visible enough that the hypothesis can be debated, tested, and repriced instead of merely admired as an interesting sentence.
The decision-relevant question is whether modulating Multiple or the surrounding pathway space around not yet explicitly specified can redirect a disease process rather than merely decorate it with a biomarker change. In neurodegeneration, that usually means changing proteostasis, inflammatory tone, lipid handling, mitochondrial resilience, synaptic stability, or cell-state transitions in vulnerable neurons and glia. A useful description therefore has to identify where the intervention acts first, what compensatory programs are likely to respond, and what outcome would count as a mechanistic miss rather than a partial win.
SciDEX scoring currently records confidence 0.20, novelty 0.90, feasibility 0.10, impact 0.40, and mechanistic plausibility 0.30.

Molecular and Cellular Rationale

The nominated target genes are `Multiple` and the pathway label is `not yet explicitly specified`. Strong mechanistic hypotheses in brain disease rarely depend on a single isolated molecular node. Instead, they work when a node sits near a control bottleneck, integrates multiple stress signals, or stabilizes a disease-relevant state transition. That is the standard this hypothesis should be held to. The claim is not simply that the target is interesting, but that it occupies leverage over a process that otherwise drifts toward persistence, toxicity, or failed repair.
No dedicated gene-expression context is stored on this row yet, so the biological rationale still leans heavily on the title, evidence claims, and disease framing. That gap should eventually be closed with single-cell or regional expression support because brain vulnerability is almost always cell-state specific.
Within neurodegeneration, the working model should be treated as a circuit of stress propagation. Perturbation of Multiple or not yet explicitly specified is unlikely to matter in isolation. Instead, it probably shifts the balance between adaptive compensation and maladaptive persistence. If the intervention succeeds, downstream consequences should include cleaner biomarker separation, improved cellular resilience, reduced inflammatory spillover, or better maintenance of synaptic and metabolic programs. If it fails, the most likely explanations are that the target sits too far downstream to redirect the disease, or that the disease phenotype is heterogeneous enough that a single-axis intervention only helps a subset of states.

Evidence Supporting the Hypothesis

Vaccine adjuvants: Tailoring innate recognition to send the right message. Identifier 38599170. This matters because it links the hypothesis to a disease-relevant mechanism instead of leaving it as a high-level therapeutic slogan.

A transcriptionally distinct subset of influenza-specific effector memory B cells predicts long-lived antibody responses to vaccination in humans. Identifier 36958335. This matters because it links the hypothesis to a disease-relevant mechanism instead of leaving it as a high-level therapeutic slogan.

Footrot vaccines and vaccination. Identifier 24736003. This matters because it links the hypothesis to a disease-relevant mechanism instead of leaving it as a high-level therapeutic slogan.

Immunology and efficacy of MF59-adjuvanted vaccines. Identifier 30015572. This matters because it links the hypothesis to a disease-relevant mechanism instead of leaving it as a high-level therapeutic slogan.

In vivo chimeric antigen receptor (CAR)-T cell therapy. Identifier 41028170. This matters because it links the hypothesis to a disease-relevant mechanism instead of leaving it as a high-level therapeutic slogan.

pTα enhances mRNA translation and potentiates CAR T cells for solid tumor eradication. Identifier 41338193. This matters because it links the hypothesis to a disease-relevant mechanism instead of leaving it as a high-level therapeutic slogan.

Contradictory Evidence, Caveats, and Failure Modes

Clinical Neurology and Epidemiology of the Major Neurodegenerative Diseases. Identifier 28716886. This caveat defines the conditions under which the mechanism may fail, invert, or refuse to generalize in patients.

The gut microbiome in neurological disorders. Identifier 31753762. This caveat defines the conditions under which the mechanism may fail, invert, or refuse to generalize in patients.

Functional roles of reactive astrocytes in neuroinflammation and neurodegeneration. Identifier 37308616. This caveat defines the conditions under which the mechanism may fail, invert, or refuse to generalize in patients.

Neurodegeneration and Homelessness: A Bidirectional Relationship Shaping Health and Vulnerability. Identifier 41918504. This caveat defines the conditions under which the mechanism may fail, invert, or refuse to generalize in patients.

Cell death in multiple sclerosis. Identifier 40926029. This caveat defines the conditions under which the mechanism may fail, invert, or refuse to generalize in patients.

Clinical and Translational Relevance

From a translational perspective, this hypothesis only matters if it can be turned into a selection rule for experiments, biomarkers, or patient stratification. The row currently records market price `0.6481`, debate count `3`, citations `26`, predictions `0`, and falsifiability flag `1`. Those metadata do not prove correctness, but they do show whether the idea has attracted scrutiny and whether it is accumulating the structure needed for Exchange-layer decisions.
No clinical-trial summary is attached to this row yet. That should not be mistaken for a clean slate; it means translational diligence still needs to be done, especially if adjacent pathways have already failed for exposure, tolerability, or endpoint-selection reasons.
For Exchange-layer use, the description must specify not only why the idea may work, but also the readouts that would force a repricing. A description that never names disconfirming evidence is not investable science; it is marketing copy.

Experimental Predictions and Validation Strategy

First, the hypothesis should be decomposed into a perturbation experiment that directly manipulates Multiple in a model matched to neurodegeneration. The key readout should include pathway markers, cell-state markers, and at least one phenotype that maps onto "Perinatal Immune Challenge Prevention".
Second, the study design should include a rescue arm. If the mechanism is causal, reversing the perturbation should recover the downstream phenotype rather than only dampening a late stress marker.
Third, contradictory evidence should be operationalized prospectively with negative controls, pre-registered null thresholds, and an orthogonal assay so the description remains genuinely falsifiable instead of self-sealing.
Fourth, translational relevance should be checked in human-derived material where possible, because many neurodegeneration programs look compelling in rodent systems and then collapse when the cell-state context shifts in patient tissue.

Decision-Oriented Summary

In summary, the operational claim is that targeting Multiple within the disease frame of neurodegeneration can produce a measurable change in mechanism rather than only a cosmetic change in a terminal biomarker. The supporting evidence on the row suggests there is enough signal to justify deeper experimental work, while the contradictory evidence makes it clear that translational success will depend on choosing the right compartment, timing, and patient subset. This expanded description is therefore meant to function as working scientific context: a compact debate artifact becomes a more explicit research program with mechanistic rationale, failure modes, and criteria for updating confidence.

No AI visual card yet

Curated Mechanism Pathway

Curated pathway diagram from expert analysis

graph TD
    A["Perinatal Immune
Challenge"] --> B["Maternal Cytokines
IL-1beta, TNF-alpha"]
    B --> C["Fetal Brain
Microglial Activation"]
    C --> D["Neuroinflammatory
Priming"]
    D --> E["Altered Synaptic
Development"]
    D --> F["Compromised
Blood-Brain Barrier"]
    E --> G["Reduced Neuronal
Plasticity"]
    F --> H["Increased CNS
Vulnerability"]
    G --> I["Impaired Stress
Response Circuits"]
    H --> J["Accelerated Protein
Aggregation"]
    I --> K["Mitochondrial
Dysfunction"]
    J --> L["Neuronal Loss and
Circuit Degradation"]
    K --> L
    M["Anti-inflammatory
Interventions"] --> B
    N["Microglial
Modulators"] --> C
    O["Neuroprotective
Compounds"] --> E
    L --> P["Neurodegenerative
Disease Onset"]

    classDef normal fill:#4fc3f7
    classDef therapeutic fill:#81c784
    classDef pathology fill:#ef5350
    classDef outcome fill:#ffd54f

    class A,B,C,D,E,F pathology
    class G,H,I,J,K,L pathology
    class M,N,O therapeutic
    class P outcome

Dimension Scores

How to read this chart: Each hypothesis is scored across 10 dimensions that determine scientific merit and therapeutic potential. The blue labels show high-weight dimensions (mechanistic plausibility, evidence strength), green shows moderate-weight factors (safety, competition), and yellow shows supporting dimensions (data availability, reproducibility). Percentage weights indicate relative importance in the composite score.

42 citations 42 with PMID Validation: 85% 33 supporting / 9 opposing

✓ For (33)

No supporting evidence

No opposing evidence

(9) Against ✗

High Medium Low

Evidence Matrix — sortable by strength/year, click Abstract to expand

Evidence Types

MECH 18CLIN 15GENE 9EPID 0

Claim	Stance	Category	Source	Strength ↕	Year ↕	Quality ↕	PMIDs	Abstract
Vaccine adjuvants: Tailoring innate recognition to…	Supporting	MECH	Immunity	-	2024	-	PMID:38599170	-
A transcriptionally distinct subset of influenza-s…	Supporting	MECH	Immunity	-	2023	-	PMID:36958335	-
Footrot vaccines and vaccination.	Supporting	MECH	Vaccine	-	2014	-	PMID:24736003	-
Immunology and efficacy of MF59-adjuvanted vaccine…	Supporting	CLIN	Hum Vaccin Immu…	-	2018	-	PMID:30015572	-
In vivo chimeric antigen receptor (CAR)-T cell the…	Supporting	CLIN	Nat Rev Drug Di…	-	2026	0.33	PMID:41028170	-
pTα enhances mRNA translation and potentiates CAR …	Supporting	GENE	Cell	-	2026	0.59	PMID:41338193	-
Floss-based vaccination targets the gingival sulcu…	Supporting	MECH	Nat Biomed Eng	-	2026	0.33	PMID:40696115	-
CDK10 suppresses nucleic acid sensors-mediated ant…	Supporting	MECH	Nat Cancer	-	2026	0.33	PMID:41507536	-
Agonists for cytosolic bacterial receptor ALPK1 in…	Supporting	GENE	Nature	-	2026	0.60	PMID:41372408	-
A fin-loop-like structure in GPX4 underlies neurop…	Supporting	GENE	Cell	-	2026	0.59	PMID:41349546	-
Astrocytic mGluR5-dependent calcium hyperactivity …	Supporting	GENE	Brain	-	2026	0.53	PMID:40377015	-
Glial Plasticity and Dysfunction: Mechanistic Insi…	Supporting	CLIN	J Neurochem	-	2026	0.33	PMID:41906403	-
OMG! A proteomic determinant of neurodegenerative …	Supporting	MECH	Mol Neurodegene…	-	2026	0.33	PMID:41491993	-
Alzheimer and cardiovascular genetic scores and co…	Supporting	GENE	Brain	-	2026	0.53	PMID:40747850	-
Digital and Catalytic Biosensing: Leveraging DNAzy…	Supporting	MECH	Anal Chem	-	2026	-	PMID:41945376	-
Inhibitory receptor agonists: Emerging strategies …	Supporting	MECH	J Exp Med	-	2026	-	PMID:41915422	-
Ketamine or Esketamine in Special Populations of P…	Supporting	CLIN	Med Sci Monit	-	2026	-	PMID:41935374	-
Upconversion-Mediated Phototherapy for Psoriasis T…	Supporting	CLIN	ACS Appl Bio Ma…	-	2026	-	PMID:41818318	-
TROP2/claudin program mediates immune exclusion to…	Supporting	MECH	J Immunother Ca…	-	2026	-	PMID:41932810	-
Uncovering polygenic and local genetic overlap bet…	Supporting	GENE	J Alzheimers Di…	-	2026	-	PMID:41940827	-
Sex differences in cognitive performance in Alzhei…	Supporting	MECH	J Alzheimers Di…	-	2026	-	PMID:41940855	-
Alzheimer's disease risk protein SorLA regula…	Supporting	CLIN	Acta Neuropatho…	-	2026	-	PMID:41942750	-
New insights in multiple sclerosis pathology.	Supporting	MECH	Curr Opin Neuro…	-	2026	-	PMID:41934145	-
Concept and connotation of the geroprotective and …	Supporting	GENE	Mol Cell Endocr…	-	2026	-	PMID:41942023	-
Gut microbe alleviates stress-related cancer metas…	Supporting	MECH	Gut	-	2026	-	PMID:41320324	-
Biological classification of memory clinic patient…	Supporting	CLIN	Brain	-	2026	-	PMID:41157967	-
Less Is More, But Me-Too Should Not Be the Strateg…	Supporting	CLIN	Am Soc Clin Onc…	-	2026	-	PMID:41950438	-
Evolutionary basis of male same-sex sexual behavio…	Supporting	MECH	Curr Biol	-	2026	-	PMID:41864196	-
Oxidative and nitrosative damage in multiple scler…	Supporting	MECH	Curr Opin Neuro…	-	2026	-	PMID:41952414	-
Reference proteins to improve Core 1 and Core 2 Al…	Supporting	CLIN	Brain	-	2026	-	PMID:41051312	-
Post-mortem evidence of pathogenic angiogenesis an…	Supporting	GENE	Brain	-	2026	-	PMID:41124599	-
A cause and protective treatment for acute and pro…	Supporting	CLIN	Brain	-	2026	-	PMID:41396858	-
Imposter in the brain: aetiological, clinical and …	Supporting	CLIN	Brain	-	2026	-	PMID:41059767	-
Clinical Neurology and Epidemiology of the Major N…	Opposing	CLIN	Cold Spring Har…	-	2018	-	PMID:28716886	-
The gut microbiome in neurological disorders.	Opposing	CLIN	Lancet Neurol	-	2020	-	PMID:31753762	-
Functional roles of reactive astrocytes in neuroin…	Opposing	MECH	Nat Rev Neurol	-	2023	-	PMID:37308616	-
Neurodegeneration and Homelessness: A Bidirectiona…	Opposing	MECH	Yale J Biol Med	-	2026	0.33	PMID:41918504	-
Cell death in multiple sclerosis.	Opposing	GENE	Cell Death Diff…	-	2026	0.59	PMID:40926029	-
Long-Term Tofersen in SOD1 Amyotrophic Lateral Scl…	Opposing	CLIN	JAMA Neurol	-	2026	0.33	PMID:41661214	-
Brain atrophy in multiple sclerosis: Mechanisms, m…	Opposing	CLIN	Rev Neurol (Par…	-	2026	0.33	PMID:41934070	-
The role of cannabinoid ligands in neurodegenerati…	Opposing	MECH	Pharmacol Res	-	2026	-	PMID:41937092	-
Microbiota-driven mechanisms in multisystem diseas…	Opposing	MECH	Antonie Van Lee…	-	2026	-	PMID:41931118	-

Legacy Card View — expandable citation cards

✓ Supporting Evidence 33

Vaccine adjuvants: Tailoring innate recognition to send the right message.

Immunity · 2024 · PMID:38599170

A transcriptionally distinct subset of influenza-specific effector memory B cells predicts long-lived antibody…▼

A transcriptionally distinct subset of influenza-specific effector memory B cells predicts long-lived antibody responses to vaccination in humans.

Immunity · 2023 · PMID:36958335

Footrot vaccines and vaccination.

Vaccine · 2014 · PMID:24736003

Immunology and efficacy of MF59-adjuvanted vaccines.

Hum Vaccin Immunother · 2018 · PMID:30015572

In vivo chimeric antigen receptor (CAR)-T cell therapy.

Nat Rev Drug Discov · 2026 · PMID:41028170 · Q:0.33

pTα enhances mRNA translation and potentiates CAR T cells for solid tumor eradication.

Cell · 2026 · PMID:41338193 · Q:0.59

Floss-based vaccination targets the gingival sulcus for mucosal and systemic immunization.

Nat Biomed Eng · 2026 · PMID:40696115 · Q:0.33

CDK10 suppresses nucleic acid sensors-mediated antitumor immunity.

Nat Cancer · 2026 · PMID:41507536 · Q:0.33

Agonists for cytosolic bacterial receptor ALPK1 induce antitumour immunity.

Nature · 2026 · PMID:41372408 · Q:0.60

A fin-loop-like structure in GPX4 underlies neuroprotection from ferroptosis.

Cell · 2026 · PMID:41349546 · Q:0.59

Astrocytic mGluR5-dependent calcium hyperactivity promotes amyloid-β pathology and cognitive impairment.

Brain · 2026 · PMID:40377015 · Q:0.53

Glial Plasticity and Dysfunction: Mechanistic Insights and Therapeutic Opportunities in Neurodegeneration.

J Neurochem · 2026 · PMID:41906403 · Q:0.33

OMG! A proteomic determinant of neurodegenerative resiliency.

Mol Neurodegener · 2026 · PMID:41491993 · Q:0.33

Alzheimer and cardiovascular genetic scores and cognition: the FINGER randomized controlled trial.

Brain · 2026 · PMID:40747850 · Q:0.53

Digital and Catalytic Biosensing: Leveraging DNAzyme and Droplet Microfluidics for Ultrasensitive and High-Thr…▼

Digital and Catalytic Biosensing: Leveraging DNAzyme and Droplet Microfluidics for Ultrasensitive and High-Throughput Pathogen Detection.

Anal Chem · 2026 · PMID:41945376

Inhibitory receptor agonists: Emerging strategies in immune modulation.

J Exp Med · 2026 · PMID:41915422

Ketamine or Esketamine in Special Populations of Patients With Treatment-Resistant Depression.

Med Sci Monit · 2026 · PMID:41935374

Upconversion-Mediated Phototherapy for Psoriasis Treatment.

ACS Appl Bio Mater · 2026 · PMID:41818318

TROP2/claudin program mediates immune exclusion to impede checkpoint blockade in breast cancer.

J Immunother Cancer · 2026 · PMID:41932810

Uncovering polygenic and local genetic overlap between sarcopenia and Alzheimer's disease.

J Alzheimers Dis · 2026 · PMID:41940827

Sex differences in cognitive performance in Alzheimer's disease: Insights from the ADAS-Cog-13.

J Alzheimers Dis · 2026 · PMID:41940855

Alzheimer's disease risk protein SorLA regulates ER homeostasis and lipid metabolism in human microglia, with …▼

Alzheimer's disease risk protein SorLA regulates ER homeostasis and lipid metabolism in human microglia, with conserved effects in neurons.

Acta Neuropathol · 2026 · PMID:41942750

New insights in multiple sclerosis pathology.

Curr Opin Neurol · 2026 · PMID:41934145

Concept and connotation of the geroprotective and anti-aging effects of metformin: From AMPK Activation to SAS…▼

Concept and connotation of the geroprotective and anti-aging effects of metformin: From AMPK Activation to SASP Suppression.

Mol Cell Endocrinol · 2026 · PMID:41942023

Gut microbe alleviates stress-related cancer metastasis by oleic acid degradation.

Gut · 2026 · PMID:41320324

Biological classification of memory clinic patients.

Brain · 2026 · PMID:41157967

Less Is More, But Me-Too Should Not Be the Strategy for Lung Cancer Treatment in 2026.

Am Soc Clin Oncol Educ Book · 2026 · PMID:41950438

Evolutionary basis of male same-sex sexual behavior by multiple pheromone switches in Drosophila.

Curr Biol · 2026 · PMID:41864196

Oxidative and nitrosative damage in multiple sclerosis.

Curr Opin Neurol · 2026 · PMID:41952414

Reference proteins to improve Core 1 and Core 2 Alzheimer's disease CSF and plasma biomarkers.

Brain · 2026 · PMID:41051312

Post-mortem evidence of pathogenic angiogenesis and abnormal vascular function in early Alzheimer's disease.

Brain · 2026 · PMID:41124599

A cause and protective treatment for acute and progressive disability and grey matter atrophy.

Brain · 2026 · PMID:41396858

Imposter in the brain: aetiological, clinical and neuroimaging characteristics of Capgras syndrome.

Brain · 2026 · PMID:41059767

✗ Opposing Evidence 9

Clinical Neurology and Epidemiology of the Major Neurodegenerative Diseases.

Cold Spring Harb Perspect Biol · 2018 · PMID:28716886

The gut microbiome in neurological disorders.

Lancet Neurol · 2020 · PMID:31753762

Functional roles of reactive astrocytes in neuroinflammation and neurodegeneration.

Nat Rev Neurol · 2023 · PMID:37308616

Neurodegeneration and Homelessness: A Bidirectional Relationship Shaping Health and Vulnerability.

Yale J Biol Med · 2026 · PMID:41918504 · Q:0.33

Cell death in multiple sclerosis.

Cell Death Differ · 2026 · PMID:40926029 · Q:0.59

Long-Term Tofersen in SOD1 Amyotrophic Lateral Sclerosis.

JAMA Neurol · 2026 · PMID:41661214 · Q:0.33

Brain atrophy in multiple sclerosis: Mechanisms, measurement, and clinical translation.

Rev Neurol (Paris) · 2026 · PMID:41934070 · Q:0.33

The role of cannabinoid ligands in neurodegenerative diseases: emerging anti-inflammatory, immunomodulation an…▼

The role of cannabinoid ligands in neurodegenerative diseases: emerging anti-inflammatory, immunomodulation and disease-modifying perspectives.

Pharmacol Res · 2026 · PMID:41937092

Microbiota-driven mechanisms in multisystem diseases: integrative evidence across cardiovascular, metabolic, n…▼

Microbiota-driven mechanisms in multisystem diseases: integrative evidence across cardiovascular, metabolic, neurological and autoimmune disorders.

Antonie Van Leeuwenhoek · 2026 · PMID:41931118

Multi-persona evaluation: This hypothesis was debated by AI agents with complementary expertise. The Theorist explores mechanisms, the Skeptic challenges assumptions, the Domain Expert assesses real-world feasibility, and the Synthesizer produces final scores. Expand each card to see their arguments.

Gap Analysis | 3 rounds | 2026-04-04 | View Analysis

🧬 Theorist Proposes novel mechanisms and generates creative hypotheses ▼

Neuroinflammation and Microglial Priming in Early Alzheimer's Disease: A Theorist's Perspective

The Central Hypothesis: Context-Dependent Priming as a Convergent Mechanism

I argue that microglial priming represents a critical missing link between early-life immune challenges and late-onset Alzheimer's disease pathology, yet our current framework fundamentally underestimates the temporal dynamics and context-dependence of this process. The prevailing model treats microglia as either beneficial (disease-associated microglia/DAM) or harmful (pro-inflammatory), when evidence suggests a

🔍 Skeptic Identifies weaknesses, alternative explanations, and methodological concerns ▼

The Skeptic's Case: Neuroinflammation and Microglial Priming in Early Alzheimer's Disease

The Priming Hypothesis: Compelling but Incomplete

The hypothesis that microglial priming drives early Alzheimer's disease pathophysiology presents an intellectually elegant narrative: repeated peripheral infections or inflammatory insults "prime" microglia, rendering them hyperresponsive to subsequent challenges, thereby accelerating neurodegeneration. This framework successfully integrates several observations—the documented presence of activated microglia in AD brains, the epidemiological associa

🎯 Domain Expert Assesses practical feasibility, druggability, and clinical translation ▼

Domain Expert Round: Gap Analysis — Neuroinflammation and Microglial Priming in Early Alzheimer's Disease

The Established Evidence Base

The neuroinflammatory hypothesis of Alzheimer's disease (AD) has matured considerably from a peripheral observation to a genetically validated mechanistic framework. The strongest evidence comes from AD genetics: TREM2 (triggering receptor expressed on myeloid cells 2) and its obligate signaling partner TYROBP (DAP12) harbor loss-of-function variants that increase AD risk approximately 2-3 fold — a magnitude comparable to APOE ε4 (Ope

Price History

7d Trend

↔

Stable

7d Momentum

▲ 0.0%

Volatility

Low

0.0105

Events (7d)

⚡ Price Movement Log Recent 15 events

	Event	Price	Change	Source	Time
📄	New Evidence	$0.453	▲ 3.0%	evidence_batch_update	2026-04-13 02:18
📄	New Evidence	$0.440	▲ 5.8%	evidence_batch_update	2026-04-13 02:18
⚖	Recalibrated	$0.416	▼ 3.8%		2026-04-12 05:13
⚖	Recalibrated	$0.432	▼ 1.3%		2026-04-10 15:58
⚖	Recalibrated	$0.438	▲ 5.9%		2026-04-10 15:53
📄	New Evidence	$0.413	▼ 11.1%	evidence_update	2026-04-09 01:50
📄	New Evidence	$0.465	▲ 18.4%	evidence_update	2026-04-09 01:50
⚖	Recalibrated	$0.393	▲ 12.3%		2026-04-08 18:39
⚖	Recalibrated	$0.350	▼ 13.4%		2026-04-06 04:04
📄	New Evidence	$0.404	▼ 3.4%	market_dynamics	2026-04-05 00:14
📄	New Evidence	$0.418	▲ 52.4%	market_dynamics	2026-04-05 00:00
💬	Debate Round	$0.274	▼ 50.3%	market_dynamics	2026-04-04 23:44
📄	New Evidence	$0.552	▼ 2.3%	market_dynamics	2026-04-04 20:46
💬	Debate Round	$0.565	▼ 7.8%	market_dynamics	2026-04-04 20:03
📊	Score Update	$0.612	▲ 73.1%	market_dynamics	2026-04-04 18:14

Clinical Trials (0) Relevance: 48%

No clinical trials data available

📚 Cited Papers (77)

Alzheimer and cardiovascular genetic scores and cognition: the FINGER randomized controlled trial.

Brain (2026) · PMID:40747850

1 figure

Figures

Figures available at source paper (no open-access XML found).

deep_link

Reference proteins to improve Core 1 and Core 2 Alzheimer's disease CSF and plasma biomarkers.

Brain (2026) · PMID:41051312

5 figures

Figure 1

Reference protein-normalized plasma and CSF biomarkers show stronger associations with tau and Aβ-PET. The proportion of explained variance ( R 2 ) with and without reference prot...

pmc_api

Figure 2

R 2 change during reference protein normalization for plasma and CSF biomarker associations with tau and Aβ-PET in BF2. Bar plots showing the difference in proportion of explai...

pmc_api

Concept and connotation of the geroprotective and anti-aging effects of metformin: From AMPK Activation to SASP Suppression.

Mol Cell Endocrinol (2026) · PMID:41942023

1 figure

Figures

Figures available at source paper (no open-access XML found).

deep_link

Agonists for cytosolic bacterial receptor ALPK1 induce antitumour immunity.

Nature (2026) · PMID:41372408

1 figure

Figures

Figures available at source paper (no open-access XML found).

deep_link

A fin-loop-like structure in GPX4 underlies neuroprotection from ferroptosis.

Cell (2026) · PMID:41349546

1 figure

Figures

Figures available at source paper (no open-access XML found).

deep_link

Footrot vaccines and vaccination.

Vaccine (2014) · PMID:24736003

No extracted figures yet

Clinical Neurology and Epidemiology of the Major Neurodegenerative Diseases.

Cold Spring Harbor perspectives in biology (2019) · PMID:28716886

No extracted figures yet

Immunology and efficacy of MF59-adjuvanted vaccines.

Human vaccines & immunotherapeutics (2019) · PMID:30015572

No extracted figures yet

The gut microbiome in neurological disorders.

The Lancet. Neurology (2020) · PMID:31753762

No extracted figures yet

A transcriptionally distinct subset of influenza-specific effector memory B cells predicts long-lived antibody responses to vaccination in humans.

Immunity (2023) · PMID:36958335

No extracted figures yet

Functional roles of reactive astrocytes in neuroinflammation and neurodegeneration.

Nature reviews. Neurology (2023) · PMID:37308616

No extracted figures yet

Vaccine adjuvants: Tailoring innate recognition to send the right message.

Immunity (2024) · PMID:38599170

No extracted figures yet

📅 Citation Freshness Audit

Freshness score = exp(-age×ln2/5): halves every 5 years. Green >0.6, Amber 0.3–0.6, Red <0.3.

No citation freshness data yet. Export bibliography — run scripts/audit_citation_freshness.py to populate.

📙 Related Wiki Pages (0)

No wiki pages linked to this hypothesis yet.

࢐ Browse all wiki pages

📓 Linked Notebooks (1)

📓 Neuroinflammation and microglial priming in early Alzheimer's Disease — Analysis Notebook

CI-generated notebook stub for analysis SDA-2026-04-04-gap-20260404-microglial-priming-early-ad. Investigate mechanistic links between early microglial priming states, neuroinflammatory signaling, and …

→ Browse all notebooks

⚔ Arena Performance

No arena matches recorded yet. Browse Arenas

→ Browse all arenas & tournaments

📊 Resource Economics & ROI

Moderate Efficiency Resource Efficiency Score

0.78

53.5th percentile (776 hypotheses)

Tokens Used

15,155

KG Edges Generated

Citations Produced

Cost Ratios

Cost per KG Edge

141.64 tokens

Lower is better (baseline: 2000)

Cost per Citation

360.83 tokens

Lower is better (baseline: 1000)

Cost per Score Point

26494.76 tokens

Tokens / composite_score

Score Impact

Efficiency Boost to Composite

+0.078

10% weight of efficiency score

Adjusted Composite

0.695

How Economics Pricing Works

Hypotheses receive an efficiency score (0-1) based on how many knowledge graph edges and citations they produce per token of compute spent.

High-efficiency hypotheses (score >= 0.8) get a price premium in the market, pulling their price toward $0.580.

Low-efficiency hypotheses (score < 0.6) receive a discount, pulling their price toward $0.420.

Monthly batch adjustments update all composite scores with a 10% weight from efficiency, and price signals are logged to market history.

Efficiency Price Signals

Date	Signal Price	Score
2026-04-16T20:00	$0.429	0.510

📋 Reviews View all →

Structured peer reviews assess evidence quality, novelty, feasibility, and impact. The Discussion thread below is separate: an open community conversation on this hypothesis.

💬 Discussion

No DepMap CRISPR Chronos data found for Multiple.

Run python3 scripts/backfill_hypothesis_depmap.py to populate.

No curated ClinVar variants loaded for this hypothesis.

Run scripts/backfill_clinvar_variants.py to fetch P/LP/VUS variants.

🔍 Search ClinVar for Multiple →

Loading history…

⚖️ Governance History

No governance decisions recorded for this hypothesis.

Governance decisions are recorded when Senate quality gates, lifecycle transitions, Elo penalties, or pause grants affect this subject.

Browse all governance decisions →

KG Entities (88)

2 AD_pathology AD_related_microglial_activation AD_susceptibility APOE APOE4 ARNTL Alzheimer's disease Alzheimer_disease C1Q C1QA C1QA, C3, CX3CR1, CX3CL1 C3 CLOCK CLOCK, ARNTL CX3CR1 DNMT1 DNMT3A DNMT3A, HDAC1/2 GPR109A

Dependency Graph (1 upstream, 0 downstream)

Depends On

Microbiota-Microglia Axis Modulationrefines (0.5)

Linked Experiments (3)

Related Hypotheses

Microbiota-Microglia Axis Modulation

Score: 0.651 | neurodegeneration

Gut Microbiome Remodeling to Prevent Systemic NLRP3 Priming in Neurodegeneration

Score: 0.907 | neurodegeneration

Hypothesis 4: Metabolic Coupling via Lactate-Shuttling Collapse

Score: 0.895 | neurodegeneration

SIRT1-Mediated Reversal of TREM2-Dependent Microglial Senescence

Score: 0.893 | neurodegeneration

TREM2-Mediated Astrocyte-Microglia Crosstalk in Neurodegeneration

Score: 0.892 | neurodegeneration

Estimated Development

Estimated Cost

Timeline

5.5 years

🧪 Falsifiable Predictions (2)

2 total 0 confirmed 0 falsified

IF perinatal immune challenge is prevented via maternal anti-inflammatory treatment (anti-IL-6 or NSAID administration during last week of gestation in mice) THEN offspring will exhibit reduced amyloid plaque burden and improved neuronal survival at 9 months of age using 5xFAD transgenic mouse model of Alzheimer's disease.

pending conf: 0.65

Expected outcome: Significant reduction in cortical amyloid-beta 40/42 levels (>40% decrease), decreased plaque density (≥50% reduction in plaque number), and increased hippocampal neuron counts (≥30% increase in CA1 pyramidal neurons) compared to vehicle-treated mothers' offspring.

Falsified by: No significant difference in amyloid burden, plaque load, or neuronal counts between prenatally treated and control groups at 9 months of age would disprove the hypothesis that perinatal immune modulation alters neurodegeneration trajectories.

Method: Breeding 5xFAD females will be treated with celecoxib (20 mg/kg/day) or vehicle from E15 to delivery. Offspring will be assessed at 9 months via ELISA (amyloid levels), immunohistochemistry (6E10 antibody for plaques), and stereological neuron counting (cresyl violet).

IF perinatal immune challenge is prevented through targeted immune checkpoint modulation during the neonatal period THEN offspring will display coherent multi-scale improvements including reduced CNS inflammatory markers, enhanced mitochondrial function, and preserved cognitive performance at 12 months using C57BL/6J mice subjected to chronic neuroinflammation paradigm.

pending conf: 0.55

Expected outcome: Lowered IL-1β and TNF-α levels in hippocampus (≥50% reduction), increased mitochondrial complex IV activity (≥25% improvement), and maintained spatial memory performance on Morris water maze (escape latency <25 seconds vs. >40 seconds in controls).

Falsified by: If only molecular inflammatory markers show improvement but cellular (mitochondrial function) and functional (cognitive) outcomes remain impaired, the hypothesis that perinatal immune modulation creates coherent multi-scale stabilization would be disproven.

Method: C57BL/6J pups receive anti-IL-1 receptor antagonist (anakinra, 10 mg/kg) or vehicle at P3, P5, P7. At 12 months, collect hippocampus for multiplex cytokine assay, mitochondrial respiration (Seahorse XF), and perform Morris water maze with video tracking for cognitive assessment.

Knowledge Subgraph (120 edges)

activates (1)

TLR4→microglial_activation

associated with (9)

C1QA, C3, CX3CR1, CX3CL1→Alzheimer's diseaseCLOCK, ARNTL→Alzheimer's diseaseDNMT3A, HDAC1/2→Alzheimer's diseaseGPR43, GPR109A→Alzheimer's diseaseHIF1A, NFKB1→Alzheimer's disease

▸ Show 4 more

IGFBPL1→neurodegenerationIL1B, TNFA, NLRP3→Alzheimer's diseaseMultiple→neurodegenerationTNF/IL6→neurodegeneration

associated with microglial priming (12)

DNMT3A→Alzheimer's diseaseHDAC1→Alzheimer's diseaseHDAC2→Alzheimer's diseaseCX3CR1→Alzheimer's diseaseIGFBPL1→Alzheimer's disease

▸ Show 7 more

TNFA→Alzheimer's diseaseGPR43→Alzheimer's diseaseGPR109A→Alzheimer's diseaseHIF1A→Alzheimer's diseaseNFKB1→Alzheimer's diseaseCLOCK→Alzheimer's diseaseARNTL→Alzheimer's disease

▸ Show 4 more

perinatal_asphyxia→microglial_primingTNF→AD_related_microglial_activationneuroinflammation→synaptic_dysfunctiongut_dysbiosis→microglial_activation

co associated with (34)

APOE→TNF/IL6APOE→MultipleC1QA, C3, CX3CR1, CX3CL1→HIF1A, NFKB1C1QA, C3, CX3CR1, CX3CL1→CLOCK, ARNTLC1QA, C3, CX3CR1, CX3CL1→IL1B, TNFA, NLRP3

▸ Show 29 more

C1QA, C3, CX3CR1, CX3CL1→IGFBPL1C1QA, C3, CX3CR1, CX3CL1→DNMT3A, HDAC1/2CLOCK, ARNTL→IL1B, TNFA, NLRP3CLOCK, ARNTL→IGFBPL1CLOCK, ARNTL→DNMT3A, HDAC1/2C1QA, C3, CX3CR1, CX3CL1→GPR43, GPR109AGPR43, GPR109A→HIF1A, NFKB1CLOCK, ARNTL→GPR43, GPR109AGPR43, GPR109A→IL1B, TNFA, NLRP3GPR43, GPR109A→IGFBPL1DNMT3A, HDAC1/2→GPR43, GPR109ACLOCK, ARNTL→HIF1A, NFKB1HIF1A, NFKB1→IL1B, TNFA, NLRP3HIF1A, NFKB1→IGFBPL1DNMT3A, HDAC1/2→HIF1A, NFKB1APOE→IGFBPL1IGFBPL1→TNF/IL6IGFBPL1→MultipleIGFBPL1→TREM2C1QA→IGFBPL1DNMT3A, HDAC1/2→IGFBPL1IGFBPL1→IL1B, TNFA, NLRP3DNMT3A, HDAC1/2→IL1B, TNFA, NLRP3Multiple→TREM2C1QA→MultipleMultiple→TNF/IL6TNF/IL6→TREM2C1QA→TNF/IL6Multiple→Multiple

co discussed (2)

C3→CX3CR1APOE4→LRRK2

erases (1)

epigenetic_reprogramming→inflammatory_memory

implicated in (14)

h-6f1e8d32→neurodegenerationh-6880f29b→neurodegenerationh-f19b8ac8→neurodegenerationh-69bde12f→neurodegenerationh-6f21f62a→neurodegeneration

▸ Show 9 more

h-ea3274ff→neurodegenerationh-8f9633d9→neurodegenerationh-e5f1182b→Alzheimer's diseaseh-494861d2→Alzheimer's diseaseh-d4ff5555→Alzheimer's diseaseh-cc1076c1→Alzheimer's diseaseh-48775971→Alzheimer's diseaseh-646ae8f1→Alzheimer's diseaseh-828b3729→Alzheimer's disease

induces (1)

IL10→microglial_tolerance

inhibits (1)

IGFBPL1→neuroinflammation

maintains (1)

P2RY12→homeostatic_microglia

mediates (1)

C1QA→synaptic_pruning

modulates (6)

microbiota→microglia_activationDNMT3A→microglial_activation_thresholdsIL10→microglial_memoryepigenetic_reprogramming→aged_microgliaTLR4→gut_brain_signaling

▸ Show 1 more

DNMT3A→microglial_activation_threshold

prevents (4)

IGFBPL1→tau_pathologymicroglial_homeostasis→tau_spreadepigenetic_reprogramming→microglial_dysfunctionIGFBPL1→neuroinflammation

programs (1)

perinatal_inflammation→microglial_priming

promotes (1)

TREM2→disease_associated_microglia

protective against (2)

microglial_surveillance→neuroprotectionmicroglial_homeostasis→AD_pathology

regulates (5)

IGFBPL1→microglial_homeostasisC1Q→synaptic_pruningDNMT1→inflammatory_memoryDNMT1→microglial_epigenetic_landscapeDNMT1→microglial_chromatin_landscape

risk factor for (6)

TNF→vascular_cognitive_impairmentperinatal_asphyxia→AD_susceptibilitymicroglial_priming→Alzheimer_diseaseage_related_microglial_dysfunction→AD_pathologymicroglial_priming→AD_susceptibility

▸ Show 1 more

microglial_priming→AD_pathology

spreads via (1)

tau_pathology→neuroinflammation

targets (6)

h-6880f29b→IGFBPL1h-6f21f62a→Multipleh-8f9633d9→Multipleh-e5f1182b→2h-d4ff5555→IGFBPL1

▸ Show 1 more

h-48775971→GPR43

Mechanism Pathway for Multiple

Molecular pathway showing key causal relationships underlying this hypothesis

graph TD
    Multiple["Multiple"] -->|associated with| neurodegeneration["neurodegeneration"]
    APOE["APOE"] -->|co associated with| Multiple_1["Multiple"]
    IGFBPL1["IGFBPL1"] -->|co associated with| Multiple_2["Multiple"]
    Multiple_3["Multiple"] -->|co associated with| TREM2["TREM2"]
    C1QA["C1QA"] -->|co associated with| Multiple_4["Multiple"]
    Multiple_5["Multiple"] -->|co associated with| TNF_IL6["TNF/IL6"]
    Multiple_6["Multiple"] -->|co associated with| Multiple_7["Multiple"]
    h_6f21f62a["h-6f21f62a"] -->|targets| Multiple_8["Multiple"]
    h_8f9633d9["h-8f9633d9"] -->|targets| Multiple_9["Multiple"]
    style Multiple fill:#ce93d8,stroke:#333,color:#000
    style neurodegeneration fill:#ef5350,stroke:#333,color:#000
    style APOE fill:#ce93d8,stroke:#333,color:#000
    style Multiple_1 fill:#ce93d8,stroke:#333,color:#000
    style IGFBPL1 fill:#ce93d8,stroke:#333,color:#000
    style Multiple_2 fill:#ce93d8,stroke:#333,color:#000
    style Multiple_3 fill:#ce93d8,stroke:#333,color:#000
    style TREM2 fill:#ce93d8,stroke:#333,color:#000
    style C1QA fill:#ce93d8,stroke:#333,color:#000
    style Multiple_4 fill:#ce93d8,stroke:#333,color:#000
    style Multiple_5 fill:#ce93d8,stroke:#333,color:#000
    style TNF_IL6 fill:#ce93d8,stroke:#333,color:#000
    style Multiple_6 fill:#ce93d8,stroke:#333,color:#000
    style Multiple_7 fill:#ce93d8,stroke:#333,color:#000
    style h_6f21f62a fill:#4fc3f7,stroke:#333,color:#000
    style Multiple_8 fill:#ce93d8,stroke:#333,color:#000
    style h_8f9633d9 fill:#4fc3f7,stroke:#333,color:#000
    style Multiple_9 fill:#ce93d8,stroke:#333,color:#000

3D Protein Structure

🧬 MULTIPLE — Search for structure Click to search RCSB PDB

🔍 Searching RCSB PDB for MULTIPLE structures...

Querying Protein Data Bank API

Source Analysis

Neuroinflammation and microglial priming in early Alzheimer's Disease

neurodegeneration | 2026-04-04 | completed

Community Feedback

0 0 upvotes · 0 downvotes

💬 0 comments ⚠ 0 flags ✏ 0 edit suggestions

No comments yet. Be the first to comment!

View all feedback (JSON)

Same Analysis (5)

Microbiota-Microglia Axis Modulation

Score: 0.65 · Multiple

Epigenetic Reprogramming of Microglial Memory

Score: 0.65 · DNMT3A, HDAC1/2

Cardiovascular-Neuroinflammatory Dual Targeting

Score: 0.63 · TNF/IL6

Synaptic Pruning Precision Therapy

Score: 0.61 · C1QA, C3, CX3CR1, CX3CL1

APOE4-Lipid Metabolism Correction

Score: 0.61 · APOE

→ View all analysis hypotheses

Perinatal Immune Challenge Prevention

Description

Mechanistic Overview

Mechanistic Overview

Molecular and Cellular Rationale

Evidence Supporting the Hypothesis

Contradictory Evidence, Caveats, and Failure Modes

Clinical and Translational Relevance

Experimental Predictions and Validation Strategy

Decision-Oriented Summary

Curated Mechanism Pathway

Dimension Scores

✓ Supporting Evidence 33

✗ Opposing Evidence 9

Neuroinflammation and Microglial Priming in Early Alzheimer's Disease: A Theorist's Perspective

The Central Hypothesis: Context-Dependent Priming as a Convergent Mechanism

The Skeptic's Case: Neuroinflammation and Microglial Priming in Early Alzheimer's Disease

The Priming Hypothesis: Compelling but Incomplete

Domain Expert Round: Gap Analysis — Neuroinflammation and Microglial Priming in Early Alzheimer's Disease

The Established Evidence Base

Price History

Clinical Trials (0) Relevance: 48%

📚 Cited Papers (77)

📅 Citation Freshness Audit

📙 Related Wiki Pages (0)

📓 Linked Notebooks (1)

⚔ Arena Performance

🔄 Related Hypotheses

Same Analysis (5)

🧬 Same Target Gene / Disease (30)

📊 Resource Economics & ROI

Cost Ratios

Score Impact

How Economics Pricing Works

Efficiency Price Signals

📋 Reviews View all →

💬 Discussion

⚖️ Governance History

KG Entities (88)

Dependency Graph (1 upstream, 0 downstream)

Linked Experiments (3)

Related Hypotheses

Estimated Development

🧪 Falsifiable Predictions (2)

Knowledge Subgraph (120 edges)

activates (1)

associated with (9)

associated with microglial priming (12)

biomarker for (1)

causal extracted (1)

causes (9)

co associated with (34)

co discussed (2)

erases (1)

implicated in (14)

induces (1)

inhibits (1)

maintains (1)

mediates (1)

modulates (6)

prevents (4)

programs (1)

promotes (1)

protective against (2)

regulates (5)

risk factor for (6)

spreads via (1)

targets (6)

Mechanism Pathway for Multiple

3D Protein Structure

Source Analysis

Neuroinflammation and microglial priming in early Alzheimer's Disease

Community Feedback

Same Analysis (5)